<DOC>
	<DOCNO>NCT02652091</DOCNO>
	<brief_summary>The primary objective study assess adherence persistence BETASERON therapy patient use BETACONNECT auto-injector device ( BETACONNECT device ) . The secondary objective study ass patient-reported satisfaction BETACONNECT device .</brief_summary>
	<brief_title>Impact BETACONNECT Auto-injector BETASERON Therapy Adherence Patient Satisfaction</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Male female great equal 18 year age Diagnosis RRMS accord revise McDonald Criteria ( 2010 ) ( CIS ) Prescribed BETASERON ( note : decision treat BETASERON must make independent participation study ) Confirmation insurance coverage BETASERON treatment Access personal computer complete online patient satisfaction survey Week 6 . Currently enrol clinical trial observational study Multiple Sclerosis treatment Documented substance abuse within previous 6 month prior study enrollment Any major laboratory value abnormality investigator believe would preclude patient participate study Any medical disorder , condition history opinion investigator would impair patient 's ability participate complete study Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Adherence</keyword>
	<keyword>Persistence</keyword>
	<keyword>Patient satisfaction</keyword>
</DOC>